

Molecular and Cellular Medicine Board Meeting Oc

10	9	8	7	6
	MR/P009948/1	MR/P009972/1	MR/P009255/1	MR/P009905/1
	MR/P010008/1	MR/P010334/1	MR/P009913/1	MR/P010164/1
	MR/P010091/1	MR/P502005/1	MR/P010032/1	MR/P010431/1
	MR/P010121/1	MR/P010156/1	MR/P009999/1	MR/P010601/1
	MR/P010393/1	MR/P010369/1	MR/P010113/1	
	MR/P010423/1	MR/P010415/1	MR/P010172/1	
	MR/P01058X/1	MR/P010504/1	MR/P010210/1	
	MR/N020117/1		MR/P010318/1	
			MR/P010342/1	
			MR/P010458/1	
			MR/P010482/1	
			MR/P010512/1	
			MR/P010539/1	
			MR/P010555/1	
			MR/P010571/1	
			MR/P01061X/1	
			MR/P01092X/1	

MR/P010016/1 was held over for consideration at the next Board meeting.

Proposals are scored by all Board or Panel members after the presentation and discussion against criteria to reflect their scientific merit. A single median score is calculated. At the end of the meeting they are then grouped into blocks on the basis of funding outcome, which may bring into consideration funding decisions aimed to provide the optimum package of investment.

Median scores of 6 and above are considered fundable, but the number of applications available at any given meeting varies. Given very strong competition, applications rarely achieve scores of 6. It is not valid to make comparisons across meetings.

Applications are listed in numerical order within blocks according to funding outcome. No ranking within blocks should be inferred.

For this meeting, 36/75 applications did not pass an initial triage.

tober 2016

5	4	3	2	1
MR/P010105/1				
MR/P010547/1				

rd meeting.

resentation by designated Board or Panel
ic excellence and potential impact, leading to a
rouped according to their median scores as a
strategic priorities and portfolio balance. Final
tment.

funding cut-off is dependent on the budget
we are only rarely able to award scores of 7,
ss different Board meetings

ig to i) their median score groups and ii) their

e stage and were not considered further.